Liquid Biopsy and Primary Brain Tumors

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Nov 13

PMID 34771592

Citations 28

Authors

Robert H Eibl

Markus Schneemann

Affiliations

Soon will be listed here.

Abstract

Two decades of "promising results" in liquid biopsy have led to both continuing disappointment and hope that the new era of minimally invasive, personalized analysis can be applied for better diagnosis, prognosis, monitoring, and therapy of cancer. Here, we briefly highlight the promises, developments, and challenges related to liquid biopsy of brain tumors, including circulating tumor cells, cell-free nucleic acids, extracellular vesicles, and miRNA; we further discuss the urgent need to establish suitable biomarkers and the right standards to improve modern clinical management of brain tumor patients with the use of liquid biopsy.

Citing Articles

A scoping review of factors influencing the implementation of liquid biopsy for cancer care.

Sheriff S, Saba M, Patel R, Fisher G, Schroeder T, Arnolda G J Exp Clin Cancer Res. 2025; 44(1):50.

PMID: 39934875 PMC: 11817833. DOI: 10.1186/s13046-025-03322-w.

Advances in Glioblastoma Diagnosis: Integrating Genetics, Noninvasive Sampling, and Advanced Imaging.

Gough R, Treffy R, Krucoff M, Desai R Cancers (Basel). 2025; 17(1.

PMID: 39796751 PMC: 11720166. DOI: 10.3390/cancers17010124.

Detection of H3F3A K27M or BRAF V600E in liquid biopsies of brain tumor patients as diagnostic and monitoring biomarker: impact of tumor localization and sampling method.

Madlener S, Stepien N, Senfter D, Mayr L, Laemmerer A, Hedrich C Acta Neuropathol. 2025; 149(1):5.

PMID: 39751690 PMC: 11698890. DOI: 10.1007/s00401-024-02842-7.

Liquid biopsy for monitoring medulloblastoma.

Eibl R, Schneemann M Extracell Vesicles Circ Nucl Acids. 2024; 3(3):280-291.

PMID: 39697492 PMC: 11648495. DOI: 10.20517/evcna.2022.36.

Cell-free DNA as a biomarker in cancer.

Eibl R, Schneemann M Extracell Vesicles Circ Nucl Acids. 2024; 3(3):195-215.

PMID: 39697490 PMC: 11648514. DOI: 10.20517/evcna.2022.20.

References

Boisselier B, Gallego Perez-Larraya J, Rossetto M, Labussiere M, Ciccarino P, Marie Y . Detection of IDH1 mutation in the plasma of patients with glioma. Neurology. 2012; 79(16):1693-8. DOI: 10.1212/WNL.0b013e31826e9b0a. View

RORKE L . Experimental production of primitive neuroectodermal tumors and its relevance to human neuro-oncology. Am J Pathol. 1994; 144(3):444-8. PMC: 1887098. View

Garcia-Romero N, Carrion-Navarro J, Areal-Hidalgo P, Ortiz de Mendivil A, Asensi-Puig A, Madurga R . V600E Detection in Liquid Biopsies from Pediatric Central Nervous System Tumors. Cancers (Basel). 2019; 12(1). PMC: 7016762. DOI: 10.3390/cancers12010066. View

Skog J, Wurdinger T, van Rijn S, Meijer D, Gainche L, Sena-Esteves M . Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10(12):1470-6. PMC: 3423894. DOI: 10.1038/ncb1800. View

Eibl R, Kleihues P, Jat P, Wiestler O . A model for primitive neuroectodermal tumors in transgenic neural transplants harboring the SV40 large T antigen. Am J Pathol. 1994; 144(3):556-64. PMC: 1887088. View

Saenz-Antonanzas A, Auzmendi-Iriarte J, Carrasco-Garcia E, Moreno-Cugnon L, Ruiz I, Villanua J . Liquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges. Cancers (Basel). 2019; 11(7). PMC: 6679205. DOI: 10.3390/cancers11070950. View

Zhao H, Shen J, Hodges T, Song R, Fuller G, Heimberger A . Serum microRNA profiling in patients with glioblastoma: a survival analysis. Mol Cancer. 2017; 16(1):59. PMC: 5346242. DOI: 10.1186/s12943-017-0628-5. View

Yang C, Wang C, Chen X, Chen S, Zhang Y, Zhi F . Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer. 2012; 132(1):116-27. DOI: 10.1002/ijc.27657. View

DUrso P, DUrso O, Damiano Gianfreda C, Mezzolla V, Storelli C, Marsigliante S . miR-15b and miR-21 as Circulating Biomarkers for Diagnosis of Glioma. Curr Genomics. 2016; 16(5):304-11. PMC: 4763968. DOI: 10.2174/1389202916666150707155610. View

10.

Sareen H, Garrett C, Lynch D, Powter B, Brungs D, Cooper A . The Role of Liquid Biopsies in Detecting Molecular Tumor Biomarkers in Brain Cancer Patients. Cancers (Basel). 2020; 12(7). PMC: 7408771. DOI: 10.3390/cancers12071831. View

11.

Lavon I, Refael M, Zelikovitch B, Shalom E, Siegal T . Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro Oncol. 2010; 12(2):173-80. PMC: 2940579. DOI: 10.1093/neuonc/nop041. View

12.

Zill O, Banks K, Fairclough S, Mortimer S, Vowles J, Mokhtari R . The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. Clin Cancer Res. 2018; 24(15):3528-3538. DOI: 10.1158/1078-0432.CCR-17-3837. View

13.

Roth P, Wischhusen J, Happold C, Chandran P, Hofer S, Eisele G . A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem. 2011; 118(3):449-57. DOI: 10.1111/j.1471-4159.2011.07307.x. View

14.

Pan Y, Long W, Liu Q . Current Advances and Future Perspectives of Cerebrospinal Fluid Biopsy in Midline Brain Malignancies. Curr Treat Options Oncol. 2019; 20(12):88. DOI: 10.1007/s11864-019-0689-3. View

15.

De Mattos-Arruda L, Mayor R, Ng C, Weigelt B, Martinez-Ricarte F, Torrejon D . Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015; 6:8839. PMC: 5426516. DOI: 10.1038/ncomms9839. View

16.

Mouliere F, Mair R, Chandrananda D, Marass F, Smith C, Su J . Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients. EMBO Mol Med. 2018; 10(12). PMC: 6284385. DOI: 10.15252/emmm.201809323. View

17.

Schwaederle M, Chattopadhyay R, Kato S, Fanta P, Banks K, Choi I . Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. Cancer Res. 2017; 77(19):5419-5427. PMC: 5626633. DOI: 10.1158/0008-5472.CAN-17-0885. View

18.

Bagley S, Nabavizadeh S, Mays J, Till J, Ware J, Levy S . Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study. Clin Cancer Res. 2019; 26(2):397-407. PMC: 6980766. DOI: 10.1158/1078-0432.CCR-19-2533. View

19.

Piccioni D, Singh Achrol A, Kiedrowski L, Banks K, Boucher N, Barkhoudarian G . Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors. CNS Oncol. 2019; 8(2):CNS34. PMC: 6713031. DOI: 10.2217/cns-2018-0015. View

20.

Deimling A, Eibl R, Ohgaki H, Louis D, von Ammon K, Petersen I . p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res. 1992; 52(10):2987-90. View